bioAffinity Technologies (BIAF) Cash from Financing Activities (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Cash from Financing Activities data on file, last reported at -$118513.0 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$118513.0, down 111.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (up 192.71% YoY), and the FY2025 annual result was $14.7 million, up 161.82% from the prior year.
• Cash from Financing Activities retreated to -$118513.0 in Q1 2026 per BIAF's latest filing, from $1.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $15.0 million in Q3 2022 and troughed at -$563556.0 in Q4 2022.
• A 5-year average of $2.0 million and a median of $301363.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 131.85% in 2022, then jumped 3412.08% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$563556.0 in 2022, then soared by 84.95% to -$84805.0 in 2023, then jumped by 2488.86% to $2.0 million in 2024, then plunged by 33.85% to $1.3 million in 2025, then plunged by 108.84% to -$118513.0 in 2026.
• Business Quant data shows BIAF's Cash from Financing Activities at -$118513.0 in Q1 2026, $1.3 million in Q4 2025, and $9.3 million in Q3 2025.